SARS-CoV-2 Omicron sublineage BA.2 replaces BA.1.1: genomic surveillance in Japan from September 2021 to March 2022

- 4
- 5 Yosuke Hirotsu^{1*}, Makoto Maejima², Masahiro Shibusawa², Yume Natori², Yuki Nagakubo^{2,3},
- Kazuhiro Hosaka², Hitomi Sueki², Hitoshi Mochizuki^{1,4,5}, Toshiharu Tsutsui⁶, Yumiko
 Kakizaki⁶, Yoshihiro Miyashita⁶, and Masao Omata^{5,7}
- 8
- ⁹ ¹Genome Analysis Center, Yamanashi Central Hospital, 1-1-1 Fujimi, Kofu, Yamanashi,
 ¹⁰ Japan
- ¹¹ ²Division of Microbiology in Clinical Laboratory, Yamanashi Central Hospital, 1-1-1 Fujimi,
- 12 Kofu, Yamanashi, Japan
- ¹³ ³Division of Genetics and Clinical Laboratory, Yamanashi Central Hospital, 1-1-1 Fujimi,
- 14 Kofu, Yamanashi, Japan
- ⁴Central Clinical Laboratory, Yamanashi Central Hospital, 1-1-1 Fujimi, Kofu, Yamanashi,
 Japan
- ¹⁷ ⁵Department of Gastroenterology, Yamanashi Central Hospital, 1-1-1 Fujimi, Kofu,
- 18 Yamanashi, Japan
- ¹⁹ ⁶Lung Cancer and Respiratory Disease Center, Yamanashi Central Hospital, 1-1-1 Fujimi,
- 20 Kofu, Yamanashi, Japan
- ²¹ ⁷The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, Japan
- 22
- 23 *Corresponding author: Yosuke Hirotsu, Genome Analysis Center, Yamanashi Central
- 24 Hospital, 1-1-1 Fujimi, Kofu, Yamanashi, Japan
- 25 Email: hirotsu-bdyu@ych.pref.yamanashi.jp
- 26 Tel: +81-55-253-7111, Fax: +81-55-253-8011
- 27 ORCID iD: 0000-0002-8002-834X
- 28 Keywords: SARS-CoV-2, variant of concern, Omicron, BA.1, BA.2
- 29 Running title: Omicron sublineage BA.2 replaces BA.1.1
- 30

31 Abstract

32 **Objective**

The new emerging Omicron strain of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is currently spreading worldwide. We aimed to analyze the genomic evolution of the shifting Omicron virus subtypes.

36 Methods

The study included 1,297 individuals diagnosed as SARS-CoV-2 positive by PCR test or antigen quantification test from September 2021 to March 2022. Samples were analyzed by whole genome sequencing analysis (n=489) or TaqMan assay (n=808).

40 Results

After the outbreak of the SARS-CoV-2 Delta strain, the Omicron strain spread rapidly in Yamanashi, Japan. BA.1.1 was the predominant sublineage of the Omicron strain from January to mid-February 2022, but the number of cases of sublineage BA.2 began to increase after mid-February, and this sublineage was shown to have replaced BA.1.1 by the end of March 2022. We observed higher viral and antigen levels of sublineage BA.2 than of sublineage BA.1.1 in nasopharyngeal swab samples. However, no difference in viral load by patient age was apparent between sublineages BA.1.1 and BA.2.

48 Conclusions

A transition from sublineage BA.1.1 to sublineage BA.2 was clearly observed over approximately one month. Omicron sublineage BA.2 was found to be more transmissible owing to its higher viral load regardless of patient age.

52

53 Introduction

54 Since the discovery of severe acute respiratory syndrome coronavirus 2 55 (SARS-CoV-2) at the end of 2019, large numbers of infections and deaths have been 56 reported. The Omicron (B.1.1.529) strain of SARS-CoV-2 was first identified in South Africa, 57 and infection with Omicron has been confirmed in 169 countries to date [1, 2]. World Health 58 Organization designated the Omicron strain as a variant of concern at the end of November 59 2021 [1]. Now several Omicron strain sublineages, such as BA.1, BA.1.1, BA.2, and BA.3, 60 have been described.

61 The Omicron strain has multiple spike protein mutations compared with other 62 variants of concern, such as the Alpha and Delta strains [2]. Consequently, there is concern 63 that serum antibody activity against the Omicron strain in vaccinated or convalescent 64 persons will be weaker than that against previous SARS-CoV-2 strains [3, 4]. In addition, for 65 some antibody therapies, the level of neutralizing activity was shown to differ between Omicron sublineages BA.1 and BA.2 [5, 6]. Omicron strains are considered to be highly 66 67 transmissible but have a relatively lower critical illness risk [7-10]. In many countries, 68 Omicron strains are rapidly increasing in prevalence and affecting medical and social 69 activities. Because the characteristics of infectivity and treatment response differ among 70 Omicron sublineages, it is important to understand the evolutionary process in real time.

In this study, we conducted whole genome sequencing analyses and TaqMan assays of SARS-CoV-2 on nasopharyngeal swab samples collected from 1,297 patients in Japan from September 2021 to March 2022 to investigate the evolution of SARS-CoV-2 strains.

75

76 Methods

77 SARS-CoV-2 diagnostic testing

78 Multiple molecular diagnostic testing platforms, including COVID-19 reverse 79 transcription-PCR performed in accordance with the protocol developed by the National 80 Institute of Infectious Diseases in Japan [11], the FilmArray Respiratory Panel 2.1 test 81 performed with the FilmArray Torch system (bioMérieux, Marcy-l'Etoile, France) [12], the 82 Xpert Xpress SARS-CoV-2 test performed with Cepheid GeneXpert (Cepheid, Sunnyvale, 83 CA, USA) [13], and the Lumipulse antigen test performed with the LUMIPULSE G600II 84 system (Fujirebio, Inc., Tokyo, Japan) were used for this study [14, 15]. All tests were 85 conducted on material obtained from nasopharyngeal swabs immersed in viral transport 86 media (Copan, Murrieta, CA, USA).

87

88 **Quantitative reverse transcription-PCR (RT-qPCR)**

To detect SARS-CoV-2, we performed one-step RT-qPCR amplifying the
nucleocapsid (N) gene of SARS-CoV-2, as we described previously [16]. The human
ribonuclease P protein subunit p30 (*RPP30*) gene was used as the internal positive control
(Integrated DNA Technologies, Coralville, IA, USA) [16].
The RT-qPCR assays were performed on a StepOnePlus Real-Time PCR System
(Thermo Fisher Scientific) with the following cycling conditions: reverse transcription at

95 50 °C for 5 min, inactivation of reverse transcription at 95 °C for 20 s, and denature,

96 annealing and extension at 45 cycles of 95 °C for 3 s, 60 °C for 30 s. The threshold was set

97 at 0.2. In accordance with the national protocol (version 2.9.1) [11], samples were assessed

as positive if a visible amplification plot was observed and as negative if no amplificationwas observed.

100

101 SARS-CoV-2 genome analysis

102 Whole genome sequencing analysis was conducted in accordance with a 103 previously described method on 489 nasopharyngeal swabs collected from patients with 104 coronavirus disease 2019 (COVID-19) from September 2021 to March 2022. In brief, 105 SARS-CoV-2 genomic RNA was reverse-transcribed into cDNA and amplified using the Ion 106 AmpliSeq SARS-CoV-2 Research Panel or Ion AmpliSeq SARS-CoV-2 Insight Research 107 Assay (Thermo Fisher Scientific, Waltham, MA, USA) on the Ion Torrent Genexus System in 108 accordance with the manufacturer's instructions [17-19]. Sequencing reads were processed, 109 and their quality was assessed using Genexus Software with SARS-CoV-2 plugins. The 110 sequencing reads were then mapped and aligned using the torrent mapping alignment 111 program. After initial mapping, a variant call was performed using the Torrent Variant Caller. 112 The COVID19AnnotateSnpEff plugin was used to annotate the variants. Assembly was 113 performed using the Iterative Refinement Meta-Assembler [20].

114 The viral clade and lineage classifications were conducted using Nextstrain [21] 115 and Phylogenetic Assignment of Named Global Outbreak Lineages (PANGOLIN) [22]. 116 Sequence data were deposited in the Global Initiative on Sharing Avian Influenza Data 117 (GISAID) EpiCoV database [23].

118

119 **TaqMan assay**

120 We used the pre-designed TaqMan SARS-CoV-2 Mutation Panel for detecting 121 SARS-CoV-2 spike $\Delta 69-70$, G339D, L452R, and/or Q493R (Thermo Fisher Scientific) using 122 808 SARS-CoV-2-positive samples (in submission). The TaqMan MGB probe for the 123 wild-type allele was labelled with VIC dye, and the probe for the variant allele was labelled 124 with FAM dye. This TaqMan probe system detected both wild-type and variant sequences of

SARS-CoV-2. TaqPath 1-Step RT-qPCR Master Mix CG was used as master mix. Real-time
 PCR was conducted on a Step-One Plus Real Time PCR System (Thermo Fisher
 Scientific).

128

129 **Results**

130 Transition of SARS-CoV-2 strain prevalence

To determine the viral lineage of SARS-CoV-2, we performed whole genome sequencing analyses or TaqMan assays using SARS-CoV-2-positive samples (n = 1,297) collected consecutively in Yamanashi, Japan from September 2021 to March 2022 (Figure 1A). During this period, we identified Delta strain (n = 159) and Omicron strain (n = 1,139). After the first case of Omicron was identified in January 2022, Omicron rapidly replaced Delta as the prevalent strain of SARS-CoV-2 (Figure 1A).

137

138 Changes in Omicron sublineages

139 The whole genome sequencing data were analyzed using PANGOLIN (version 140 3.1.20), and BA.1 (n = 5), BA.1.1 (n = 992), and BA.2 (n = 142) were identified as 141 sublineages of Omicron (Figure 1B). Sublineage BA.1.1 was the dominant sublineage of 142 Omicron from January to mid-February 2022; however, the incidence of sublineage BA.2 143 increased from mid-February 2022 onward, with this sublineage becoming dominant by the 144 end of March (Figure 1B and 1C). The average frequency for the seven-day period from 145 March 8 to March 14 was 62.2% (51/82) for sublineage BA.1.1 and 37.8% (31/82) for 146 sublineage BA.2, whereas from March 15 to March 21 it was 29.3% (27/92) for sublineage 147 BA.1.1 and 70.7% (65/92) for sublineage BA.2. These results indicate an extremely rapid 148 replacement of sublineage BA.1.1 by sublineage BA.2 and a higher transmissibility of 149 sublineage BA.2 compared with sublineage BA.1.1.

- 150
- 151

Viral load of Omicron sublineages

152 To investigate the underlying factors for the high transmissibility of Omicron 153 sublineage BA.2, we performed an RT-gPCR analysis of the viral load in the 154 nasopharyngeal swabs collected from patients infected with sublineage BA.1.1 (n = 748) or 155 sublineage BA.2 (n = 118). The median viral load (log_{10} copies/mL) was 5.7 (range: 0.2–7.9) 156 for sublineage BA.1.1 versus 6.4 (range: 0.3-8.2) for sublineage BA.2 (Figure 2A). The 157 median Ct value for sublineage BA.1.1 was 19 (range: 11-38) versus 17 (range: 10-38) for 158 sublineage BA.2 (Figure 2B). There are significant differences in the viral load between 159 cases of sublineage BA.1.1 and sublineage BA.2 (Figure 2A, $p = 4.8 \times 10^{-4}$, Student's *t*-test) 160 and Ct value (Figure 2B, $p = 1.6 \times 10^{-3}$, Student's *t*-test).

161 Of the 866 samples, 827 were tested for SARS-CoV-2 antigen, and the percentage 162 of samples with high antigen levels was examined. The percentage of specimens with 163 antigen levels of >5000 pg/mL was 57.3% (386/711) for sublineage BA.1.1 and 69% 164 (80/116) for sublineage BA.2, indicating that sublineage BA.2 had higher antigen levels (p =165 0.004, chi-squared test). However, the median age of infected patients was not significantly 166 different between these sublineages (35 years [range: 0–101 years] for BA.1.1 vs. 34.5 167 years [range: 0-90 years] for BA.2; p = 0.1, Student's *t*-test) (Figure 2C). These results 168 indicate that the viral load in nasopharyngeal swabs is higher for sublineage BA.2 than for 169 sublineage BA.1.1 and that sublineage BA.2 is more contagious.

170 We next examined whether the viral load varied with patient age. There was no 171 apparent correlation between patient age and viral load or Ct value for either sublineage 172 BA.1.1 or BA.2 (Figure 3D and 3E). The Pearson's correlation coefficients for sublineage 173 BA.1.1 were r = -0.0075 (p = 0.84) for patient age and viral load and r = 0.0070 (p = 0.85) 174 for patient age and Ct value, and those for sublineage BA.2 were r = -0.032 (p = 0.73) for 175 patient age and viral load and r = 0.034 (p = 0.71) for patient age and Ct value (Figures 2D 176 and 2E). These results indicate that the viral load remained fairly high in Omicron-infected 177 patients regardless of their age.

178

179 **Discussion**

This study indicates that after the expansion of the SARS-CoV-2 Delta strain, a rapid spread of the Omicron strain occurred. Sublineage BA.1 was very minor in Japan when Omicron was first discovered. First, sublineage BA.1.1 expanded dominantly and was then gradually replaced by sublineage BA.2. The results of the present study show that the amount of viral load in the nasopharyngeal swab was higher for sublineage BA.2 than for sublineage BA.1.1. These epidemiological and viral characteristic results indicate that Omicron sublineage BA.2 is more transmissible than sublineage BA.1.1.

187 Previous reports showed that sublineage BA.2 has a lower Ct value (i.e., higher 188 viral load) compared with sublineages BA.1 and BA.1.1 [24-26]. The findings of the present 189 study are consistent with those reports, and this difference could be one reason for the 190 higher infectivity of sublineage BA.2. In Denmark, England, India, the Philippines, and South 191 Africa, where Omicron strains were predominantly sublineage BA.1 in the early stages of the 192 outbreak, sublineage BA.2 later became predominant [27]. Furthermore, reinfection with 193 sublineage BA.2 after infection with sublineage BA.1 can occur, although it is rare [28]. 194 Therefore, there is concern that the prevalence of the BA.2 sublineage may increase in the 195 future.

196

The relationship between age and SARS-CoV-2 viral load of other strains was

197 shown previously [29-33]; however, no data on Omicron sublineages were reported. 198 Previous studies suggested that the SARS-CoV-2 viral load tends to be higher in young 199 children than in adults, whereas other data suggest that the viral load does not vary by age 200 group [29-33]. In this study, no obvious differences in viral load by age group were observed 201 for either the Omicron BA.1.1 or BA.2 sublineages. In general, viral load peaks in the early 202 phase of infection and then gradually declines; hence, the timing of sampling relative to the 203 onset of symptoms is an important factor [34]. Because the time between onset and 204 sampling was not taken into account in the present study, our data are limited by sampling 205 bias. However, our data are derived from random sampling, therefore these results are 206 expected to better reflect real-world conditions. Although a high incidence of household 207 COVID-19 infections stemming from young children has been reported [35], our results 208 indicate that the Omicron strain retains a fairly high viral load across age groups, which may 209 contribute to the high infectivity of the Omicron strain and its accelerated spread. These data 210 provide insights for determining appropriate COVID-19 prevention and control measures for 211 homes, schools, workplaces, and facilities for the elderly during the spread of Omicron strain 212 viruses.

213 Recombinant variants may emerge in communities where SARS-CoV-2 strains 214 with different genomic architecture are co-circulating [36]. Recently, a new hybrid strain 215 (AY.4/BA.1 recombinant, EPI ISL 10819657), which has the properties of both the Delta 216 and Omicron strains, was reported in France [23]. This hybrid virus has been detected in 217 several countries, including Belgium, Germany, Denmark, and the Netherlands. There is 218 also evidence for co-infection and recombination events between Delta and Omicron strains 219 in the same patient [37]. Recombinant viruses BA.1 and BA.2 (named XE) were also 220 reported from the United Kingdom [38]. It is not yet fully understood whether these hybrids 221 are highly infectious, pathogenic, or resistant to antibodies or therapy. Therefore, it is 222 necessary to survey the hybrid viruses to see if there is likely to be an explosion of infections. 223 Genomic epidemiological analysis of SARS-CoV-2 strains and variants should be continued 224 to monitor future virus trends.

225

226 Acknowledgements

We thank all medical and ancillary hospital staff for their support. We thank Katie Oakley, PhD, from Edanz (<u>https://ip.edanz.com/ac</u>) for editing a draft of this manuscript.

229

Funding: This work was supported by a Grant-in-Aid for the Genome Research Project from
 Yamanashi Prefecture (to M.O. and Y.H.), the Japan Society for the Promotion of Science
 (JSPS) KAKENHI Early-Career Scientists JP18K16292 (to Y.H.), a Grant-in-Aid for Scientific

7

Research (B) 20H03668 (to Y.H.), a Research Grant for Young Scholars (to Y.H.), the YASUDA Medical Foundation (to Y.H.), the Uehara Memorial Foundation (to Y.H.) and Medical Research Grants from the Takeda Science Foundation (to Y.H.).

236

237 **Declaration of interest**

- 238 None.
- 239

240 References

2411.World Health Organization. Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant242of Concern. 2021.

243 2. Julia LM, Ginger T, Alaa AL, Manar A, Marco C, Emily H, et al. outbreak.info.

Iketani S, Liu L, Guo Y, Liu L, Chan JFW, Huang Y, et al. Antibody evasion properties of
 SARS-CoV-2 Omicron sublineages. Nature. 2022. doi: 10.1038/s41586-022-04594-4.

4. Yu J, Collier A-rY, Rowe M, Mardas F, Ventura JD, Wan H, et al. Neutralization of the
SARS-CoV-2 Omicron BA.1 and BA.2 Variants. New England Journal of Medicine. 2022. doi:
10.1056/NEJMc2201849.

Bruel T, Hadjadj J, Maes P, Planas D, Seve A, Staropoli I, et al. Serum neutralization of
 SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies.
 Nature Medicine. 2022. doi: 10.1038/s41591-022-01792-5.

252 6. Takashita E, Kinoshita N, Yamayoshi S, Sakai-Tagawa Y, Fujisaki S, Ito M, et al.
253 Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2. New England
254 Journal of Medicine. 2022. doi: 10.1056/NEJMc2201933.

7. Wolter N, Jassat W, Walaza S, Welch R, Moultrie H, Groome M, et al. Early
assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data
linkage study. The Lancet. 2022;399(10323):437-46. doi: 10.1016/S0140-6736(22)00017-4.

Christensen PA, Olsen RJ, Long SW, Snehal R, Davis JJ, Saavedra MO, et al. Signals
 of significantly increased vaccine breakthrough, decreased hospitalization rates, and less severe
 disease in patients with COVID-19 caused by the Omicron variant of SARS-CoV-2 in Houston,
 Texas. The American Journal of Pathology. 2022. doi: 10.1016/j.ajpath.2022.01.007.

2629.Veneti L, Bøås H, Bråthen Kristoffersen A, Stålcrantz J, Bragstad K, Hungnes O, et al.263Reduced risk of hospitalisation among reported COVID-19 cases infected with the SARS-CoV-2264Omicron BA.1 variant compared with the Delta variant, Norway, December 2021 to January 2022.265Eurosurveillance.2022;27(4):2200077.265doi:

266 doi:<u>https://doi.org/10.2807/1560-7917.ES.2022.27.4.2200077</u>.

26710.Espenhain L, Funk T, Overvad M, Edslev SM, Fonager J, Ingham AC, et al.268Epidemiological characterisation of the first 785 SARS-CoV-2 Omicron variant cases in Denmark,

 269
 December
 2021.
 Eurosurveillance.
 2021;26(50):2101146.
 doi:

 270
 doi:<u>https://doi.org/10.2807/1560-7917.ES.2021.26.50.2101146</u>.
 doi:
 doi:
 doi:

11. Shirato K, Nao N, Katano H, Takayama I, Saito S, Kato F, et al. Development of
Genetic Diagnostic Methods for Novel Coronavirus 2019 (nCoV-2019) in Japan. Jpn J Infect Dis.
2020;73(4):304-7 doi: 10.7883/yoken.JJID.2020.061. PubMed PMID: 32074516.

Hirotsu Y, Maejima M, Shibusawa M, Amemiya K, Nagakubo Y, Hosaka K, et al.
Analysis of Covid-19 and non-Covid-19 viruses, including influenza viruses, to determine the
influence of intensive preventive measures in Japan. J Clin Virol. 2020;129:104543. doi:
10.1016/j.jcv.2020.104543

13. Hirotsu Y, Maejima M, Shibusawa M, Natori Y, Nagakubo Y, Hosaka K, et al. Direct
comparison of Xpert Xpress, FilmArray Respiratory Panel, Lumipulse antigen test, and RT-qPCR
in 165 nasopharyngeal swabs. BMC Infectious Diseases. 2022;22(1):221. doi:
10.1186/s12879-022-07185-w.

Hirotsu Y, Maejima M, Shibusawa M, Amemiya K, Nagakubo Y, Hosaka K, et al.
Prospective Study of 1,308 Nasopharyngeal Swabs from 1,033 Patients using the LUMIPULSE
SARS-CoV-2 Antigen Test: Comparison with RT-qPCR. International Journal of Infectious
Diseases. 2021. doi: https://doi.org/10.1016/j.ijid.2021.02.005.

15. Hirotsu Y, Maejima M, Shibusawa M, Nagakubo Y, Hosaka K, Amemiya K, et al.
Comparison of Automated SARS-CoV-2 Antigen Test for COVID-19 Infection with Quantitative
RT-PCR using 313 Nasopharyngeal Swabs Including from 7 Serially Followed Patients.
International Journal of Infectious Diseases. 2020. doi: https://doi.org/10.1016/j.ijid.2020.08.029.

16. Hirotsu Y, Mochizuki H, Omata M. Double-quencher probes improve detection
sensitivity toward Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in a
reverse-transcription polymerase chain reaction (RT-PCR) assay J Virol Methods.
2020;284:113926. doi: 10.1016/j.jviromet.2020.113926

Hirotsu Y, Omata M. Detection of R.1 lineage severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) with spike protein W152L/E484K/G769V mutations in Japan.
PLOS Pathogens. 2021;17(6):e1009619. doi: 10.1371/journal.ppat.1009619.

Hirotsu Y, Omata M. Discovery of a SARS-CoV-2 variant from the P.1 lineage harboring
K417T/E484K/N501Y mutations in Kofu, Japan. Journal of Infection. 2021;82(6):276-316. doi:
https://doi.org/10.1016/j.jinf.2021.03.013.

Hirotsu Y, Omata M. SARS-CoV-2 B.1.1.7 lineage rapidly spreads and replaces R.1
lineage in Japan: Serial and stationary observation in a community. Infection, Genetics and
Evolution. 2021;95:105088. doi: https://doi.org/10.1016/j.meegid.2021.105088.

303 20. Shepard SS, Meno S, Bahl J, Wilson MM, Barnes J, Neuhaus E. Viral deep sequencing
 304 needs an adaptive approach: IRMA, the iterative refinement meta-assembler. BMC Genomics.

305 2016;17:708. doi: 10.1186/s12864-016-3030-6. PubMed PMID: 27595578; PubMed Central
 306 PMCID: PMCPMC5011931.

307 21. Hadfield J, Megill C, Bell SM, Huddleston J, Potter B, Callender C, et al. Nextstrain:
308 real-time tracking of pathogen evolution. Bioinformatics. 2018;34(23):4121-3. doi:
309 10.1093/bioinformatics/bty407. PubMed PMID: 29790939; PubMed Central PMCID:
310 PMCPMC6247931.

Rambaut A, Holmes EC, O'Toole A, Hill V, McCrone JT, Ruis C, et al. A dynamic
nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology. Nat Microbiol.
2020;5(11):1403-7. doi: 10.1038/s41564-020-0770-5. PubMed PMID: 32669681.

Shu Y, McCauley J. GISAID: Global initiative on sharing all influenza data - from vision
to reality. Euro Surveill. 2017;22(13). doi: 10.2807/1560-7917.ES.2017.22.13.30494. PubMed
PMID: 28382917; PubMed Central PMCID: PMCPMC5388101.

Qassim SH, Chemaitelly H, Ayoub HH, AlMukdad S, Tang P, Hasan MR, et al. Effects
of BA.1/BA.2 subvariant, vaccination, and prior infection on infectiousness of SARS-CoV-2
Omicron infections. medRxiv. 2022:2022.03.02.22271771. doi: 10.1101/2022.03.02.22271771.

25. Chadeau-Hyam M, Tang D, Eales O, Bodinier B, Wang H, Jonnerby J, et al. Omicron
BA.1/BA.2 variant transition in the Swedish population reveals higher viral quantity in BA.2
casesThe Omicron SARS-CoV-2 epidemic in England during February 2022. medRxiv.
2022:2022.03.10.22272177. doi: 10.1101/2022.03.10.22272177.

324 26. Kirsebom FCM, Andrews N, Stowe J, Toffa S, Sachdeva R, Gallagher E, et al.
325 COVID-19 Vaccine Effectiveness against the Omicron BA.2 variant in England. medRxiv.
326 2022:2022.03.22.22272691. doi: 10.1101/2022.03.22.22272691.

27. Emma B. Hodcroft. CoVariants: SARS-CoV-2 Mutations and Variants of Interest. 2021.
28. Stegger M, Edslev SM, Sieber RN, Cäcilia Ingham A, Ng KL, Tang M-HE, et al.
Occurrence and significance of Omicron BA.1 infection followed by BA.2 reinfection. medRxiv.
2022:2022.02.19.22271112. doi: 10.1101/2022.02.19.22271112.

Baggio S, L'Huillier AG, Yerly S, Bellon M, Wagner N, Rohr M, et al. Severe Acute
Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Viral Load in the Upper Respiratory Tract of
Children and Adults With Early Acute Coronavirus Disease 2019 (COVID-19). Clinical Infectious
Diseases. 2020;73(1):148-50. doi: 10.1093/cid/ciaa1157.

335 30. Colson P, Fournier P-E, Delerce J, Million M, Bedotto M, Houhamdi L, et al. Culture and
identification of a "Deltamicron" SARS-CoV-2 in a three cases cluster in southern France.
medRxiv. 2022:2022.03.03.22271812. doi: 10.1101/2022.03.03.22271812.

338 31. Madera S, Crawford E, Langelier C, Tran NK, Thornborrow E, Miller S, et al.
339 Nasopharyngeal SARS-CoV-2 viral loads in young children do not differ significantly from those
340 in older children and adults. Scientific Reports. 2021;11(1):3044. doi:

341 10.1038/s41598-021-81934-w.

342 32. Heald-Sargent T, Muller WJ, Zheng X, Rippe J, Patel AB, Kociolek LK. Age-Related
343 Differences in Nasopharyngeal Severe Acute Respiratory Syndrome Coronavirus 2
344 (SARS-CoV-2) Levels in Patients With Mild to Moderate Coronavirus Disease 2019 (COVID-19).
345 JAMA Pediatrics. 2020;174(9):902-3. doi: 10.1001/jamapediatrics.2020.3651.

346 33. Ochoa V, Díaz FE, Ramirez E, Fentini MC, Carobene M, Geffner J, et al. Infants
347 Younger Than 6 Months Infected With SARS-CoV-2 Show the Highest Respiratory Viral Loads.
348 The Journal of Infectious Diseases. 2021;225(3):392-5. doi: 10.1093/infdis/jiab577.

349 34. Jones TC, Biele G, Mühlemann B, Veith T, Schneider J, Beheim-Schwarzbach J, et al.
350 Estimating infectiousness throughout SARS-CoV-2 infection course. Science.
351 2021;373(6551):eabi5273. doi: doi:10.1126/science.abi5273.

352 35. Paul LA, Daneman N, Schwartz KL, Science M, Brown KA, Whelan M, et al.
353 Association of Age and Pediatric Household Transmission of SARS-CoV-2 Infection. JAMA
354 Pediatrics. 2021;175(11):1151-8. doi: 10.1001/jamapediatrics.2021.2770.

355 36. Jackson B, Boni MF, Bull MJ, Colleran A, Colquhoun RM, Darby AC, et al. Generation
356 and transmission of interlineage recombinants in the SARS-CoV-2 pandemic. Cell.
357 2021;184(20):5179-88.e8. doi: <u>https://doi.org/10.1016/j.cell.2021.08.014</u>.

358 37. Bolze A, Basler T, White S, Rossi AD, Wyman D, Roychoudhury P, et al. Evidence for
359 SARS-CoV-2 Delta and Omicron co-infections and recombination. medRxiv.
360 2022:2022.03.09.22272113. doi: 10.1101/2022.03.09.22272113.

361 38. UK Health Security Agency. SARS-CoV-2 variants of concern and variants under
 362 investigation in England, Technical briefing 39. 2022.

363

364



366

367 Figure 1. Changes in Omicron strain prevalence

368 (A) SARS-CoV-2 strains identified from September 2021 to March 2022. Orange boxes

369 indicate Delta strains, and blue boxes indicate Omicron strains. (B, C) Sublineage of

370 Omicron strains detected from January 2022 to March 2022, indicated by BA.1 (pink),

371 BA.1.1 (green), and BA.2 (blue). The number of samples detected per day (B) and the

372 frequency of detection (C) are shown.



373

374

Figure 2. Viral load and age of infected patients for sublineages BA.1. and BA.2.

(A, B) The viral load and Ct values in Omicron sublineages BA.1.1 (n = 748) and BA.2 (n =

118) were analyzed by RT-qPCR. Box plots show the viral load (A) and Ct values (B) in

BA.1.1 and BA.2. (C) Box plot shows the age of patients infected with sublineage BA.1.1 or

BA.2. (D, E) Relationship between patient age and viral load (D) or Ct value (E). Pearson's

380 correlation coefficient (r) is noted in the figures. The gray background of the regression line

indicates the 95% confidence interval.